REVIEW article

Front. Bioeng. Biotechnol.

Sec. Biosafety and Biosecurity

Volume 13 - 2025 | doi: 10.3389/fbioe.2025.1605263

Bacteriophages against Salmonella Enteritidis: Challenges and Opportunities

Provisionally accepted
Nallelyt Segundo-ArizmendiNallelyt Segundo-Arizmendi1,2Alejandra Paola Flores-CoriaAlejandra Paola Flores-Coria3Janeth Gómez-GarcíaJaneth Gómez-García3Efrén HernándezEfrén Hernández1ANGELICA MENESES-ACOSTAANGELICA MENESES-ACOSTA1*
  • 1Facultad de Farmacia de la Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico
  • 2Autonomous University of the State of Morelos, Cuernavaca, Morelos, Mexico
  • 3Universidad Latinoamericana, Cuernavaca, Morelos, Mexico

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Salmonella spp. is the most common pathogen transmitted to humans through contaminated water and food. Due to its ability to infect both animals and humans, as well as the spread of antibiotic-resistant strains, this pathogen has become a priority for food and pharmaceutical industries. Consequently, research and development of treatments to combat infections caused by Salmonella spp. are ongoing. One of the most promising strategies is the phage therapy (PT) which is based on the use of very specific viruses that infect this pathogenic bacterium without any action over the host and which use has shown effectiveness. Now a days, at least 41 companies worldwide market phage therapy products mainly for use in the food sector to reduce the transmission chain of Salmonella spp. to humans. However, the complex production processes required to ensure product quality, stability, safety, and efficacy, as well as the need for regulatory frameworks for phage therapy, present limitations to the global application of this strategy seems to be a limitation to promote its use all over the world as a pharmaceutical product. Thus, this work presents a literature review on state-of-the-art of PT, analysing the opportunities and challenges that are present to consider such a therapy as an emerging treatment for antibiotic resistance of Salmonella sp.

Keywords: Bacteriophages, phage therapy, salmonellosis, Salmonella spp., Phage regulation, phage products

Received: 03 Apr 2025; Accepted: 27 Jun 2025.

Copyright: © 2025 Segundo-Arizmendi, Flores-Coria, Gómez-García, Hernández and MENESES-ACOSTA. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: ANGELICA MENESES-ACOSTA, Facultad de Farmacia de la Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material